189 related articles for article (PubMed ID: 24641502)
1. Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies.
Protti MP; De Monte L; Di Lullo G
Tissue Antigens; 2014 Apr; 83(4):237-46. PubMed ID: 24641502
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
3. Role of distinct CD4(+) T helper subset in pathogenesis of oral lichen planus.
Wang H; Zhang D; Han Q; Zhao X; Zeng X; Xu Y; Sun Z; Chen Q
J Oral Pathol Med; 2016 Jul; 45(6):385-93. PubMed ID: 26693958
[TBL] [Abstract][Full Text] [Related]
4. Differentiation and Regulation of T
Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
Front Immunol; 2021; 12():669474. PubMed ID: 34012451
[TBL] [Abstract][Full Text] [Related]
5. T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells.
Wang W; Sung N; Gilman-Sachs A; Kwak-Kim J
Front Immunol; 2020; 11():2025. PubMed ID: 32973809
[TBL] [Abstract][Full Text] [Related]
6. CD4 T Helper Cell Subsets and Related Human Immunological Disorders.
Zhu X; Zhu J
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126494
[TBL] [Abstract][Full Text] [Related]
7. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors.
Ossendorp F; Mengedé E; Camps M; Filius R; Melief CJ
J Exp Med; 1998 Mar; 187(5):693-702. PubMed ID: 9480979
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Differentiation of Effector CD4
Read KA; Powell MD; Sreekumar BK; Oestreich KJ
Methods Mol Biol; 2019; 1960():75-84. PubMed ID: 30798522
[TBL] [Abstract][Full Text] [Related]
9. Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.
Bernard D; Ventresca MS; Marshall LA; Evelegh C; Wan Y; Bramson JL
Mol Ther; 2010 Jun; 18(6):1224-32. PubMed ID: 20179673
[TBL] [Abstract][Full Text] [Related]
10. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
11. Ikaros Zinc Finger Transcription Factors: Regulators of Cytokine Signaling Pathways and CD4
Powell MD; Read KA; Sreekumar BK; Oestreich KJ
Front Immunol; 2019; 10():1299. PubMed ID: 31244845
[TBL] [Abstract][Full Text] [Related]
12. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design.
Zeng G
J Immunother; 2001; 24(3):195-204. PubMed ID: 11394496
[TBL] [Abstract][Full Text] [Related]
13. T helper cells plasticity in inflammation.
Cosmi L; Maggi L; Santarlasci V; Liotta F; Annunziato F
Cytometry A; 2014 Jan; 85(1):36-42. PubMed ID: 24009159
[TBL] [Abstract][Full Text] [Related]
14. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
15. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy.
Topalian SL
Curr Opin Immunol; 1994 Oct; 6(5):741-5. PubMed ID: 7826529
[TBL] [Abstract][Full Text] [Related]
16. Identification of MHC class II-restricted tumor antigens recognized by CD4+ T cells.
Wang RF
Methods; 2003 Mar; 29(3):227-35. PubMed ID: 12725788
[TBL] [Abstract][Full Text] [Related]
17. Helios is associated with CD4 T cells differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3 expression.
Serre K; Bénézech C; Desanti G; Bobat S; Toellner KM; Bird R; Chan S; Kastner P; Cunningham AF; Maclennan IC; Mohr E
PLoS One; 2011; 6(6):e20731. PubMed ID: 21677778
[TBL] [Abstract][Full Text] [Related]
18. Quantitative and Qualitative Analysis of Tumor-Associated CD4⁺ T Cells.
Di Lullo G; De Monte L; Doglioni C; Protti MP
Methods Mol Biol; 2016; 1393():37-51. PubMed ID: 27033214
[TBL] [Abstract][Full Text] [Related]
19. MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.
Poli C; Raffin C; Dojcinovic D; Luescher I; Ayyoub M; Valmori D
Haematologica; 2013 Feb; 98(2):316-22. PubMed ID: 22875619
[TBL] [Abstract][Full Text] [Related]
20. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
